Cart
sales@molnova.com
BLU0588
CAS No. 2810747-78-3
BLU0588( —— )
Catalog No. M35361 CAS No. 2810747-78-3
BLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 472 | In Stock |
|
| 5MG | 426 | In Stock |
|
| 10MG | 625 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1283 | In Stock |
|
| 100MG | 1758 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBLU0588
-
NoteResearch use only, not for human use.
-
Brief DescriptionBLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.
-
DescriptionBLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research.
-
In Vitro——
-
In VivoAnimal Model:female NOD-SCID mice harboring FLC PDX tumors (6-8-week-old, FLC PDX shRNA cell lines or Hep3B cells were implanted)Dosage:30 mg/kg Administration:Orally, once daily, 34 days Result:Inhibited tumor growth in mice, by day 34 tumor growth was inhibited by 48.5%.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2810747-78-3
-
Formula Weight423.51
-
Molecular FormulaC26H25N5O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (196.76 mM; Ultrasonic (<60°C)
-
SMILESO=C(N[C@@H]1C2=C(C=CC=C2)C[C@H]1N1CCCC1)C1=CC=C(C2=C3C=CNC3=NC=C2)N=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Stefanie S. Schalm, et al. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. Gastro Hep Advances. Volume 2, Issue 3, 2023, Pages 307-321.
molnova catalog
related products
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
-
BMS-927711
BMS-927711 is a highly potent, oral calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki value of 0.027 nM.
-
Apoatropine
Reference standards.
